Strategies
Focus
A research enterprise of Tripep's size and financial resources must strive to focus its limited internal resources. In the coming year, Tripep's resources will be concentrated on the development of the company's main projects, ChronSeal and ChronVac-C®. Largely, projects in preclinical phases will be developed by Tripep's collaboration partners at Swedish and foreign universities in the coming year.
Collaborations
To optimize its resources, Tripep runs its research projects both in-house and through collaboration agreements with strategic partners. Such collaborations enable Tripep to manage projects cost-efficiently and participate in more research projects, thereby reducing its dependence on individual projects. To ensure the commercial value of research results remains in the company, Tripep has contracts with university researchers regarding the transfer of ownership rights on their discoveries to Tripep.
Patents
Tripep's proactive patent strategy safeguards its intellectual property, which is crucial for a biotech company. Tripep's strategy is to create effective protection for its products and technologies in its key regions-North America, Europe and Asia. Initially, the strategy is to apply for patents in the US. Tripep is using the US patent bureau Knobbe Martens Olson & Bear to manage patent issues.
Funding
Financing a biotech company's development-phase activities may be achieved by outlicensing the company's technologies to established pharmaceutical companies for onward clinical development, through partnerships or issuing new shares.